0.5140
02-May-25 15:45:00
15 minutes delayed
Stocks
-0.0105
-2.00%
Today's range
0.5100 - 0.5373
ISIN
N/A
Source
NASDAQ
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
19 Jan 2021 07:30:01 By Nasdaq GlobeNewswire
Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021
04 Jan 2021 07:30:00 By Nasdaq GlobeNewswire